Table 1.
Clinical characteristics of the cohort of patients with recurrent uLMS (n=62)
| Variable | N (%) |
|---|---|
| Median age at diagnosis (yrs) | |
| Median (range) | 53.5 (32.0-74.0) |
| FIGO Stage at diagnosis | |
| 1 | 45 (71) |
| 2 | 7 (11) |
| 3 | 2 (3) |
| 4 | 4 (6) |
| N/A | 4 (6) |
| Adjuvant chemotherapy following primary surgery | 19 (31) |
| Doxorubicin | 1 (5) |
| Doxorubicin/Ifosfamide | 1 (5) |
| Gemcitabine/Docetaxel or Paclitaxel | 10 (53) |
| Gemcitabine/Docetaxel/Doxorubicin | 2 (10) |
| Cisplatin/Paclitaxel | 1 (5) |
| Cisplatin/Ifosfamide | 1 (5) |
| N/A | 2 (10) |
| Adjuvant radiation following primary surgery | 7 (11) |
| Whole Pelvic | 7 (100) |
| Hormonal therapy following primary surgery | 3 (4.8) |
| Aromatase Inhibitor | 3 (100) |
| Median time to recurrence (months) | |
| Median (95%CI) | 18.3 (13.3-23.3) |
| Median age at recurrence (years) (range) | 57.0 (35.2-76.9) |
| Residual at recurrence surgery | |
| None | 58 (94) |
| Gross | 4 (6.5) |
| <1cm | 2 (50) |
| ≥1cm | 2 (50) |
| Adjuvant chemotherapy following recurrence surgery | 10 (16) |
| Doxorubicin/Ifosfamide | 4 (40) |
| Gemcitabine | 2 (20) |
| Gemcitabine/Docetaxel or Paclitaxel | 4 (40) |
| Mesna, Doxorubicin, Ifosfamide, Dacarbazine | 1 (10) |
| Adjuvant radiation following recurrence surgery | 10 (16) |
| Whole Pelvic | 10 (100) |
| Hormonal therapy following recurrence surgery | 10 (16) |
| Aromatase Inhibitor | 6 (60) |
| Selective Estrogen Receptor Modulators | 1 (10) |
| Progesterone | 3 (30) |
| Overall Survival | |
| Median (95%CI) | 54.2 (25.8-82.4) |
| Dead of Disease | 45 (71) |